MedTrace Logo

A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome

NCT04978779 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2023-11-18

No results posted yet for this study

Summary

Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of VIP152 as monotherapy or in combination with a BTKi in patients with Chronic Lymphocytic Leukemia (CLL) or Richter Syndrome

Conditions

  • Relapsed Non Hodgkin Lymphoma
  • Chronic Lymphocytic Leukemia
  • Refractory Chronic Lymphocytic Leukemia
  • Richter Syndrome
  • MYC Amplification
  • MYC Overexpression
  • MYC Translocation

Interventions

DRUG

VIP152

Weekly IV infusion for 28 day cycles.

DRUG

BTKi

Taken per local prescribing information

Sponsors & Collaborators

  • Vincerx Pharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Vincerx Study Director · Vincerx Pharma, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-16
Primary Completion
2023-05-26
Completion
2023-05-26
FDA Drug
Yes

Countries

  • United States
  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04978779 on ClinicalTrials.gov